ASCO 2021: Adjuvant olaparib PARP improves outcomes in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations
When treated with adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy, patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, […]
